Answers are grounded in this paper and cite their sources.
Review demonstrates the clinical utility of circulating tumor biomarkers across multiple malignancies, highlighting a shift toward minimally invasive precision oncology.
The advent of “liquid biopsy” as a tool for the detection of molecular abnormalities has paved the way for its use not only in diagnosis but also in screening, monitoring of therapeutic response, and surveillance. Detection of circulating tumor deoxyribonucleic acid and circulating tumor cells are among the commonly employed liquid biopsy targets that are changing the diagnostic and treatment landscape. By offering a minimally invasive method for disease monitoring and aiding treatment decision-making, liquid biopsy techniques are increasingly being incorporated into clinical management algorithms for multiple malignancies.
No takes yet. Share an insight, caveat, or question.
Prabhat Ganju (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: